摘要
目的 探讨人附睾蛋白4(human epididymis protein-4,HE4)与糖类抗原125(CA125)联合检测在早期卵巢癌诊断中的应用价值.方法 选取本院2014年8月至2015年5月收治的20例卵巢癌(甲组)、20例卵巢良性病变患者(乙组),选取同时期健康体检者40例作为对照组,对三组对象血清HE4与CA125水平进行测定.结果 甲组患者血清HE4为(483.13±26.98) pmol/L,明显高于对照组和乙组,P< 0.05;甲组CA125为(345.81±40.34) pmol/L,显著高于对照组和乙组(P<0.05);HE4联合CA125检测敏感性高于两者单独检测,特异性高于CA125单独检测,低于HE4单独检测(P<0.05).结论 血清HE4与CA125联合检测早期卵巢癌价值优于两者单独检测,可明显提高诊断敏感性,为疾病的诊断、治疗提供专业参考,值得临床推广应用.
Objective To investigate the application value of human epididymis protein 4 (epididymis protein-4 human,HE4) and carbohydrate antigen 125 (CA125) in the diagnosis of early ovarian cancer.Methods 20 patients with ovarian cancer (group A) and 20 patients with benign ovarian lesions (group B) treated at our hospital from August,2014 to May,2015 were selected.40 healthy subjects taking physical examination during the same period were selected as a control group.The serum levels of HE4 and CA125 of these three groups were measured.Results The serum levels of HE4 and CA125 was (483.13±26.98) pmol/L and (345.81±40.34)pmol/L in group A,which were significantly higher than those in the control group and group B (P〈0.05).The detection sensitivity of the combination of HE4 CA125 was higher than that of either HE4 or CA125.The specificity of the combination of HE4 CA125 was higher than that of CA125 and lower than that of HE4(P〈0.05).Conclusions The value of the combined detection of serum HE4 and CA125 in the diagnosis of early ovarian cancer is better than that of either one and can significantly improve the diagnostic sensitivity and provide professional reference for the diagnosis of the disease,so it is worth being clinically generalized.
出处
《国际医药卫生导报》
2016年第14期2167-2169,共3页
International Medicine and Health Guidance News
关键词
卵巢癌
HE4
CA125
诊断
Ovarian carcinoma
Diagnosis
Ovarian carcinoma
Diagnosis